AQEMIA Advances with $100M Funding Milestone
Deal News | Dec 10, 2024 | Elaia Partners SAS
AQEMIA, a start-up specializing in artificial intelligence-driven drug discovery, has successfully raised $38 million in its latest funding round. This round was led by Cathay Innovation, marking their entry as a new investor, while past investors like Wendel, Bpifrance Large Venture, Eurazeo, and Elaia Partners SAS also participated. This funding comes a year after AQEMIA signed a €140 million contract with pharmaceutical giant Sanofi. The funding marks a significant milestone for AQEMIA, pushing its total funding to reach $100 million. The involvement of prominent investment groups demonstrates the potential seen in AQEMIA's innovative approach to drug discovery leveraging generative AI technologies.
Sectors
- Biotechnology
- Financial Services
- Artificial Intelligence
Geography
- France – AQEMIA is a French start-up, and several investors and contracts, including the one with Sanofi, are based in France.
Industry
- Biotechnology – The article centers around AQEMIA, a company involved in drug discovery using biotechnology enhanced by artificial intelligence.
- Financial Services – Involves various prominent investment firms like Cathay Innovation, Wendel, Bpifrance Large Venture, Eurazeo, and Elaia participating in the funding.
- Artificial Intelligence – AQEMIA's use of generative AI for drug discovery is a core aspect of its business model.
Financials
- $38 million – The amount AQEMIA raised in the latest funding round.
- $100 million – The total funding milestone reached by AQEMIA after the latest round.
- €140 million – The value of the contract signed between AQEMIA and Sanofi a year ago.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AQEMIA | Target company | Company | AQEMIA is a start-up focused on AI-driven drug discovery. |
| Elaia Partners SAS | Investor | Company | A French private equity firm that has invested in AQEMIA. |
| Cathay Innovation | Lead investor | Company | A global investment firm leading the latest financing round for AQEMIA. |
| Wendel | Investor | Company | An investment company that participated in the funding. |
| Bpifrance Large Venture | Investor | Company | A French investment firm that participated in the funding. |
| Eurazeo | Investor | Company | A French investment company that participated in the funding. |
| Sanofi | Contract partner | Company | A pharmaceutical giant that previously signed a €140 million contract with AQEMIA. |